Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712

PURPOSE: The addition of rituximab to fludarabine-based regimens in chronic lymphocytic leukemia (CLL) has been shown to produce high response rates with extended remissions. The long-term follow-up of these regimens with respect to progression, survival, risk of secondary leukemia, and impact of ge...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Woyach, Jennifer A., Ruppert, Amy S., Heerema, Nyla A., Peterson, Bercedis L., Gribben, John G., Morrison, Vicki A., Rai, Kanti R., Larson, Richard A., Byrd, John C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2011
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3084002/
https://ncbi.nlm.nih.gov/pubmed/21321292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.1811
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items